We studied the a-and P-adrenoceptor activity and catecholamine and cAMP levels in 112 children and infants admitted to the hospital for diagnostic or inte~entional catheterization of tetralogy of Fallot, ventricular septa1 defects with or without hypertension, pulmonary stenosis, coarctation of the aorta, and various complex cyanotic congenital cardiac diseases and compared them with 14 children undergoing transcatheter occlusion of patent ductus arteriosus with insignificant left-to-right-shunts. The mean total platelet a-adrenoceptor density of the study population was elevated by 73%. Both the increases in acyanotic ( p < 0.05) and cyanotic ( p < 0.005) patients as well as the difference between the two groups ( p < 0.01) were significant.
In congenital heart diseases, cyanosis has been associated with various alterations in cardiac sympathetic activity (1) (2) (3) (4) (5) (6) . In acute hypoxemia, for example, stimulation of the sympathetic activity results in increased heart rate and cardiac output as a compensatory mechanism to maintain adequate oxygen supply (7, 8) , whereas in chronic situations, such as in cyanotic congenital heart disease, several complex events probably contribute toward the mechanism(s) to sustain adequate oxygen supply (9) . In animal models of chronic congenital cardiac disorders, the cardiac output returns to normal, but the sympathetic tone remains elevated (5, 6) . Such a persistently elevated sympathetic tone may be a result of chronic stimulation of adrenoceptors by catecholamines and can ultimately lead to down-regulation of especially P-adrenoceptor density (10) (11) (12) (13) (14) . Indeed, an attenuation of P-adrenoceptor activity has been documented in animal models of cyanotic congenital diseases, leading to suggestions that cyanosis causes a down-regulation of P-adrenoceptors in patients with congenital heart diseases (15) (16) (17) (18) (19) . However, it is not certain whether such alterations in the P-adrenoceptor activity under these study conditions are caused directly by cyanosis or are primarily a product of some changes such as increased sympathetic function as a result elevated circulating catecholamines caused by experimental 5 6 DZIMIRI ET AL. lacking in the literature based on human studies in support of the notion that cyanosis stimulates the sympathetic activity in patients with congenital heart disorders. Furthermore, in contrast to P-adrenoceptors, there is only limited documentation at present of a-adrenoceptor studies in children with such disorders. One such study by McGrath et al. (20) suggests that in patients with TOF, for example, the infundibular a-adrenoceptor fiber content may be increased irrespective of whether or not these patients are cyanotic. It appears therefore that a -and P-adrenoceptors may be influenced in various ways by different congenital heart disorders. We have hypothesized that the levels of adrenoceptor activity may express the mode by which the sympathetic nervous system responds to hemodynamic or other changes in these patients, and that such alterations would depend primarily on the type of congenital heart disease rather than the presence or absence of cyanosis. To test this point of view, we compared the a -and P-adrenoceptor activity and plasma catecholamine and cAMP levels in patients with TOF, ventricular septal defects with and without pulmonary hypertension, PST, COA, and other CPL.
METHODS

Study population.
The study population consisted of 112 infants, children, and young adults ranging in age from 8 mo to 20 y (median age 36 mo; range 235 mo), admitted for diagnostic or interventional cardiac catheterization of various cyanotic and acyanotic congenital heart diseases. Fifty-five (49%) of the patients were male and fifty-seven (51%) were female. The patients were divided into five groups: the first group consisted of 30 patients with TOF, the second group were 22 patients with ventricular septal defects associated with LRS with or without pulmonary hypertension, the third group were 32 patients with PST, the fourth were 10 patients with COA, and fifth were 18 patients with CPL unrelated to any of the above. Fourteen consecutive acyanotic children and infants (10 girls and 4 boys, median age 48 mo, range 144 mo) admitted for transcatheter occlusion of patent ductus arteriosus with pulmonary to systemic flow ratio (Qp/Qs) of less than 1.5 were elected as the control group of the same age. Fully informed consent was obtained from all patients or family members before participating in the study. The study was performed in accordance with the rules and regulations laid down by the Hospital's Ethics Committee and Clinical Protocols Committee.
Binding studies. Blood samples were drawn in EDTA tubes between 0800 and 1000 h on the morning of admission to the hospital. The blood was layered over Leukoprep (Becton Dickinson, Heidelberg, Germany) and centrifuged at 1500 X g for 15 min. The supernatant was carefully collected into a test tube for catecholamine and cAMP determination; the fluffy layer was resuspended in Tris buffer and centrifuged at 200 X g for 10 min. The resultant pellet enriched with lymphocytes was suspended in TrisJEDTA for the evaluation of P-adrenoceptor activity, and the supernatant was recentrifuged at 1800 X g to obtain the platelet pellet which was similarly suspended in TrisEDTA buffer for a-adrenoceptor studies. The platelet a-adrenoceptor density and binding affinity were determined by specific binding of [3~]yohimbin (83 Ci/mmol, New England Nuclear Corp., England). Approximately 1 X lo7 cells were suspended in Tris buffer containing 50 mM Tris-HC1 (pH 7.4), 5 mM EDTA, 120 mM NaCl, 10 mM MgCl,, 0.8 mM ascorbic acid, and 0.3 mM catechol and incubated with 0.5-8.0 nM [3~]yohimbin at room temperature for 30 min in a final volume of 300 pL. The reaction was terminated by addition of iced-cold Tris buffer and subsequent filtration through Whatman GF/B filters (Whatman Inc., Clifton, NJ) on a Brandel Harvester (Biomed Research and Development Laboratories, Inc., Gaithersburg, MD). The cells were rapidly washed twice using 5 mL of cold Tris buffer. The filters were dried, and the radioactivity was counted in 10 mL Optifluor scintillation fluid (Packard, Meridian, CT). Nonspecific binding was determined by the addition of 50 p M phentolamine. The difference between the platelet binding to [3~]yohimbin in the absence and presence of phentolamine was considered specific binding.
The lymphocyte P-adrenoceptor density and binding affinity were determined by specific binding of [125~]iodocyanopindolo1 (2200 Ci/mmol, New England Nuclear Corp., Hertfordshire, England). Approximately 1 X lo5 cells were suspended in Tris buffer (pH 7.4) containing 120 mM NaCl, 10 mM MgCl,, 0.8 mM ascorbic acid, and 0.3 mM catechol and incubated with 10-160 pM [125~]iodocyanopindolol at 37OC for 60 min in a final volume of 300 pL. The reaction was similarly terminated and the cells washed by addition of icecold Tris buffer and subsequent filtration through Whatman GFIB filters on a Brandel harvester. The filters were dried, and the radioactivity was counted on LKB y counter. Nonspecific binding was determined by the addition of 5.0 p M propranolol. The difference between the lymphocyte binding to [125~]iodocyanopindolol in the presence and absence of propranolol was considered specific binding. All assays were conducted in duplicate.
Plasma catecholamine and cAMP levels. The catecholamines norepinephrine, epinephrine, and dopamine were extracted from plasma using activated alumina according to the method of Anton and Sayre (21) , and assessed by high performance liquid chromatography (Waters model 501 solvent delivery system) using electrochemical detector (Waters model 460, Miliford, MA). cAMP was determined by radioimmunoassay (Amersham, Buckinghamshire, England). Drugs used were [3~]yohimbin, [125~]iodocyanopindolol (New England Nuclear, Hertfordshire, England) and phentolamine (Sigma Chemical Co., St. Louis, MO). All other reagents were of analytical grade.
Statistical analysis. The receptor binding affinity (Kd) and the maximal number of binding sites (B,,,) were calculated from Scatchard saturation binding isotherms using Ligand software (Munson and Rodbard, 1980). The significance of differences was estimated by t test using Sigmaplot statistical package (1993) and analysis of variance and regression analysis using Statgraphics software (Statistical Graphics Corporation 1988), taking the probability levels of less than 0.05 as indicating significant difference. Experimental data are given as mean 2 SEM. 
RESULTS
In this study, we classified our patients into five groups as having TOF (mean arterial oxygen saturation, 82.1 t 2.5%), ventricular septa1 defects (LRS, mean pulmonary arterial pressure, 41.0 + 4.4 mm Hg, Qp/Qs ratio 3.51 + 0.47), PST (right ventricular diastolic pressure 13.1 + 1.3 mm Hg, right ventricular systolic pressure 110.1 + 6.3 mm Hg,), COA (systolic gradient, 47.7 + 4.9 mm Hg), or complex cyanotic lesions not related to any of the above groups (CPL). The adrenoceptor studies were performed in 55 of the 112 patients with congenital heart diseases. Acyanotic children and infants with PDA were considered to be functionally normal with respect to their sympathetic activity, and were therefore used as a control group of similar age range. In this population, the average density of the platelet a-adrenoceptors (B,,,) was 2.62 t 0.53 fmol per lo7 cells. Compared with these controls, the total a-adrenoceptor density of all patients together was increased by 73%. First, we explored the potential relationships between these changes in the adrenoceptor activity and some predictor variables such as age, arterial oxygen saturation, and systemic pressures. Multiple regression analysis of the data indicated that there was no significant variation with age in the a-adrenoceptor density (correlation coefficient -0.08). On the other hand, the total a-adrenoceptor density showed a correlation coefficient of -0.48 versus arterial oxygen saturation. This value improved significantly to -0.89 for the comparison of the same parameters for the TOF group (n = 13), showing that the a-adrenoceptor density increased inversely with arterial oxygen saturation. When the patients were grouped as cyanotic (CYN, oxygen saturation of less than 95%) and acyanotic (ACY), the former exhibited an a-adrenoceptor density of 6.90 + 0.50 fmol (n = 19), whereas the latter showed a value of 4.64 % 0.35 fmol (n = 36). Both values were significantly ( p < 0.05) higher than the PDA group. The difference in the two study populations was also significant ( p < 0.01). Figure 1 compares the average a-adrenoceptor densities of the ACY and CYN with those of the PDA patients. When the patients were classified according to the type of lesions, all groups, except the COA, showed a significant increase in their mean a-adrenoceptor densities. These results are depicted in Figure 2 . It can be seen from the figure that, although COA was not significantly different, it was nonetheless 24% higher than PDA. Furthermore, comparison the systolic gradient and the a-adrenoceptor density of the COA group showed regression coefficients of -0.66, suggesting a weak negative correlation with the density.
The K, for the a-adrenoceptor affinity to [3~]-yohimbin binding was elevated by 40%. It exhibited a regression coefficient of -0.40 versus the arterial oxygen saturation. This value also increased significantly to -0.79 for the TOF group. Moreover, the elevation in the K, value was significant in CYN ( p < 0.05), but not ACY, showing similarly that the a-adrenoceptor binding affinity increased with decreasing arterial oxygen saturation in these patients. The K, was also increased in all congenital groups, but significant changes were observed in the TOF and PST patients only (Table 1) . On the other hand, although the K, value for the COA group was not significant, its correlation coefficient with the systemic gradient was 0.97, suggesting a strong positive relationship for the two variables for this group of patients. Furthermore, the mean pulmonary arterial pressure and right ventricular pressure of the patients with pulmonary stenosis showed no correlation with the a-adrenoceptor activity, also suggesting that the alterations in these pressures are probably not involved in the changes in a-adrenoceptor activity in these patients.
The lymphocyte P-adrenoceptor density of the control group was 7.98 + 0.92 fmol per lo6 cells. In contrast to a-adrenoceptors, the total P-adrenoceptor density of the study patients was attenuated by 27%. Neither the total P-adrenoceptor density ( r = 0.09) nor the binding affinity ( r = -0.05) showed good correlation with the degree of oxygen saturation. In fact, the density was attenuated significantly to 5.46 t 0.42 fmol (p < 0.05) in the ACY, but nonsignificantly to 6.70 + 0.5 fmol per lo6 cells in the CYN group. There was no significant difference between either the CYN and PDA, or between the two study populations (Fig. 1) . Based on the type of disease, all five congenital groups experienced a decrease in P-adrenoceptor density. However, only the LRS and PST densities showed significant difference from that of the PDA group ( p < 0.01).
These results are shown in Figure 3 . There was also no significant difference between the various groups and the PDA 58 DZIMIRI ET AL. -PDA TOF LRS PST COA C P L Figure 3 . The 0-adrenoceptor densities in children and infants with TOF (n = 13), LRS (n = 6), PST (n = 21), COA (n = 9), and CPL (n = 6) compared with that of the children undergoing transcatheter occlusion of PDA (n = 9).
in their 0-adrenoceptor affinities toward [125~]iodocyanopindolo1 binding (Table 1) . The total plasma catecholamines were all elevated, but cAMP remained unchanged. Norepinephrine was increased by 42%, epinephrine by 41%, dopamine by 97%. Based on the t test, the increase in norepinephrine and epinephrine was significant only in the PST group, and that of dopamine in all except LRS. Although the other groups were not statistically different from PDA, the percentage increases were nonetheless remarkable (Table 2) . Moreover, the analysis of variance (ANOVA) followed by Scheffe's test showed a p value of 0.049 for norepinephrine, <0.00001 for epinephrine, 0.003 for dopamine, and 0.53 for CAMP, indicative of high significance for the increases in the plasma levels of all three catecholamines at 95% confidence level. If we consider the mean values, the order of magnitude of change versus control was PST, COA, CPL, LRS, and TOF for norepinephrine; PST, COA, TOF, CPL, and LRS for epinephrine; PST, CPL, COA, TOF, and LRS for dopamine.
DISCUSSION
The results of the present study demonstrate that platelet a-adrenoceptor density is dependent on the degree of arterial oxygen saturation. The increase in density was significant in both acyanotic and cyanotic patients with various congenital heart diseases. The present findings also indicate that the difference in the two populations, as well as between the various congenital groups and the PDA were similarly well marked. To our knowledge, this is the first study demonstrating comparatively such trends in a-adrenoceptors in children with congenital heart diseases. A recent study by McGrath et al. (20) found that the infundibular a-adrenoceptor fiber content is increased, whereas there is no difference in the densities of the ACY and CYN patients with TOF. In the present study, the correlation of both the a-adrenoceptor density and binding affinity of the TOF group with the degree of cyanosis was significantly better than between the arterial oxygen saturation and these variables in patients with congenital diseases as a whole. This suggests a strong relationship between the increase in a-adrenoceptor activity and the degree of cyanosis in these patients. It is particularly noteworthy that both the PST and LRS densities were comparatively higher than that of the complex cyanotic congenital cardiac diseases group, and that this increase was most significant in the PST group. To begin with, it should be noted that only four of the 32 PST patients Values are given as mean i SEM and concentrations are picograms/ml of plasma. * p < 0.05 and ** p < 0.001 compared with the PDA value.
were cyanotic, whereas all complex cyanotic congenital patients had cyanosis. This implies that, if cyanosis were the only determinant factor for the observed increase in density, then the complex cyanotic congenital cardiac diseases group should actually exhibit the highest, and the PST the smallest, elevation. Put together, these observations lead to the conclusion that the alterations in a-adrenoceptor activity are basically an effect of the congenital diseases on the sympathetic function, which can be enhanced by cyanosis. The argument that the alterations in sympathetic activity were probably a product of the disease rather than the presence of cyanosis in these patients is strengthened by the findings that the decrease in both the density and the binding affinity of P-adrenoceptors showed no correlation with the degree of cyanosis, and that the attenuation in P-adrenoceptor activity was significant in the acyanotic rather than in the cyanotic patients. Furthermore, it is also interesting to note that, as in the case of the a-adrenoceptors, it was the PST and LRS groups that also exhibited the most significant alterations in P-adrenoceptor density, whereas CPL was not significantly different from the PDA group. The same argument can therefore be advanced, purporting the reverse trends, if the presence of cyanosis played a major role in the decrease in P-adrenoceptor density. It seems therefore reasonable to conclude that the attenuation of P-adrenoceptor activity is probably not related to the level of oxygen saturation in these patients. The function of these receptors has been investigated extensively in animal models of cyanotic congenital heart disease (1-11). However, the results have not been very consistent. Although some investigators have reported a chamber-specific attenuation in the cardiac P-adrenoceptor density (17) (18) (19) , others have observed differential regulation (6) , no change (22) , or even an increase under chronic hypoxic experimental conditions (23) . Nonetheless, some of these findings deserve some comment with respect to our present findings. First, Bernstein et al. (6) have argued that desensitization of P-adrenoceptors during chronic hypoxia is due to a decrease in total cell receptor number and is not associated with receptor sequestration from sarcolemmal membrane to cytosolic sites, implying therefore that the changes in the P-adrenoceptor activity was a result of their down-regulation. In the present study, we observed a parallel increase in the a-adrenoceptor, and a parallel decrease in P-adrenoceptor responsiveness to ligand binding with receptor density. Similarly, this may be an indication that, in these patients, the sympathetic activity is stimulated leading to an up-regulation of a-adrenoceptor and down-regulation of the 0-adrenoceptors. A further point of interest in this regard is how these observations can be interpreted with respect to the myocardial a -and P-adrenoceptor functional state in patients with congenital heart disorders. Some previous studies have shown that lymphocyte P,-adrenoceptor density correlates well with that of the myocardial P,-adrenoceptors (24-26), suggesting therefore that alteration(s) in the activity of the former may reflect on the changes related to the latter population. On the other hand, not much is known about the relationship(s) between changes in the peripheral and those in myocardial a-adrenoceptor activity. Accordingly, only very limited inferences can be derived from the currently available literature regarding the potential relationship between the observed changes in the peripheral and those of the myocardial adrenoceptors. Further studies are therefore necessary to define more precisely the relevance of these changes in adrenoceptor activity in various cardiac disorders. Nonetheless, it can be speculated that the alterations in the adrenoceptor activities in our patients probably express the mode by which the sympathetic nervous system adapts itself to some hemodynamic changes resulting directly or indirectly from these congenital heart disorders.
Although the down-regulation of P-adrenoceptors has been well described especially in heart failure associated with various diseases (12, 13) , the function of a-adrenoceptors in heart diseases is still ill-defined. In heart failure, the down-regulation of P-adrenoceptors has been associated with elevated plasma catecholamines, especially norepinephrine (27) (28) (29) (30) (31) , whereas changes in a-adrenoceptors appear to be more closely associated with elevations in epinephrine concentrations (32) (33) (34) . Although, based on the t test, the elevation in plasma norepinephrine and epinephrine levels was significant only for the PST group, and dopamine in all except the LRS; the percentage increases were similarly remarkable for the other groups. As suggested by the analysis of variance followed by Scheffe's test, the increases especially in epinephrine and dopamine are probably significant for all groups. One possible explanation why particularly the norepinephrine and epinephrine values did not reach statistical significance in some of these patients is the wide range of the values, compounded by the low numbers of patients in the control group. Until now, not much attention has been paid with regard to changes in plasma dopamine levels in cardiac diseases. Although only very little speculation can be advanced at present on the possible mechanism(s) leading to the increase in dopamine levels, it seems nonetheless probable that their extent of elevation cannot be a mere coincidence. It can, therefore, be reasonably assumed that the alterations in the adrenoceptor activity were accompanied by a well marked increase in the plasma levels of all catecholamines in the various groups. One important notion gaining wider acknowledgment in this regard is the recent suggestion that, in heart failure, for example, the a-adrenoceptors may be mobilized to provide inotropic support to the failing heart (34-36). Although most of the patients in the present study had no congestive heart failure, the extent to which the a-adrenoceptors are elevated, accompanied by the large increase in catecholamine levels can still be conceived as suggesting a similar stimulation of these receptors in congenital heart diseases, possibly as a compensatory response to the down-regulation of the P-adrenoceptor subtypes. This is an interesting point which certainly calls for further investigation. In addition to this, the fact that most significant changes in receptor activity and catecholamine levels were observed in PST patients seems to suggest further that pressure overload exerts the most significant changes on the sympathetic activity in these patients. However, further studies are required to facilitate more precise inferences.
In summary, the present study demonstrates a significant elevation in a-adrenoceptor and an attenuation of P-adrenoceptor density in patients with congenital heart diseases. It appears that cyanosis may enhance these changes in a-adrenoceptor density, but is not a prerequisite for these alterations to occur, and appears to exert no influence on the P-adrenoceptor density. The changes in adrenoceptor activity are asso--ciated with an elevation in plasma catecholamine, but no alterations in CAMP concentrations. It can therefore be concluded that the sympathetic nervous system appears to respond --to certain congenital heart diseases by up-regulating a-adrenoceptor and down-regulating the P-adrenoceptor activity.
